









Markets
/
Stocks
/
nasdaq-pypd
/

PolyPid Ltd

PYPD



View Detailed Chart

3.450USD

-0.050-1.43%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

54.01MMarket Cap

LossP/E TTM



PolyPid Ltd

3.450

-0.050-1.43%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-1.43%

5 Days

-0.58%

1 Month

-2.27%

6 Months

+19.38%

Year to Date

+13.49%

1 Year

-0.29%

View Detailed Chart

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

122 / 175

Overall Ranking

468 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

12.500

Target Price

+257.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Undervalued

The company’s latest PE is -0.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.60M shares, increasing 15.47% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.